Skip to main content

Advertisement

Table 2 Clinical trials of STING agonists in cancer therapy

From: STING: a master regulator in the cancer-immunity cycle

Identifier STING agonist Sponsor/ collaborator Study tittle Cancer types Status
NCT00863733 DMXAA (ASA 404) Cancer Research UK and Cancer Society Auckland Study of DMXAA (Now Known as ASA404) in Solid Tumors Solid Tumors Completed
NCT00856336 DMXAA (ASA 404) Antisoma Research Phase I Safety Study of DMXAA in Refractory Tumors Refractory Tumors Completed
NCT00832494 DMXAA (ASA 404) Antisoma Research Phase II Study of DMXAA (ASA404) in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer Completed
NCT01299415 DMXAA (Vadimezan™) Novartis Safety and Pharmacokinetics of ASA404 When Given Together with Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor Solid Tumors Terminated
NCT01290380 DMXAA (ASA 404) Novartis A Study to Evaluate the Effects of ASA404 Alone or in Combination with Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients with Advanced Solid Tumor Malignancies Solid Tumor Malignancies Terminated
NCT01299701 DMXAA (ASA 404) Novartis A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients with Solid Tumors Advanced Solid Tumors Terminated
NCT01278758 DMXAA (ASA 404) Novartis A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients with Impaired Renal Function and Patients with Normal Renal Function Metastatic Cancer Terminated
NCT01285453 DMXAA (ASA 404) Novartis Safety and Tolerability of ASA404 Administered in Combination with Docetaxel in Japanese Patients with Solid Tumors Advanced or Recurrent Solid Tumors Completed
NCT01278849 DMXAA (ASA 404) Novartis An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of ASA404 in Adult Cancer Patients with Impaired Hepatic Function Histologically-proven and Radiologically-confirmed Solid Tumors Terminated
NCT00674102 DMXAA (ASA 404) Novartis An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination with Paclitaxel and Carboplatin in Japanese Patients with Non-Small Cell Lung Cancer Non-small Cell Lung Cancer Completed
NCT01071928 DMXAA (ASA 404) Hoosier Cancer Research Network And Novartis Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma Urothelial Carcinoma Withdrawn
NCT00856336 DMXAA (ASA 404) Antisoma Research Phase I Safety Study of DMXAA in Refractory Tumors Refractory Tumors Completed
NCT00832494 DMXAA (ASA 404) Antisoma Research Phase II Study of DMXAA (ASA404) in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer Completed
NCT01240642 DMXAA (ASA 404) Novartis An Open-label, Dose Escalation Multi-Center Study in Patients with Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404 Metastatic Cancer with Impaired Renal Function Metastatic Cancer with Normal Renal Function Terminated
NCT00111618 DMXAA (ASA 404) Antisoma Research Study of AS1404 With Docetaxel in Patients with Hormone Refractory Metastatic Prostate Cancer Prostate Cancer Completed
NCT01057342 DMXAA (ASA 404) Swiss Group for Clinical Cancer Research Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients with Extensive-Stage Small Cell Lung Cancer Lung Cancer Completed
NCT01031212 DMXAA (ASA 404) University of California, San Francisco and Novartis ASA404 in Combination with Carboplatin/Paclitaxel/Cetuximab in Treating Patients with Refractory Solid Tumors Tumors Withdrawn
NCT00662597 DMXAA (ASA 404) Novartis ASA404 or Placebo in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer Terminated
NCT03937141 MIW815 (ADU-S100) Aduro Biotech, Inc Efficacy and Safety Trial of ADU-S100 and Anti-PD1 in Head and Neck Cancer Metastatic head and neck cancer Recurrent head and neck cancer Recruiting Phase 2
NCT02675439 MIW815 (ADU-S100) Aduro Biotech, Inc. and Novartis Safety and Efficacy of MIW815 (ADU-S100) +/− Ipilimumab in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Solid tumors Lymphomas Recruiting Phase 1
NCT03172936 MIW815 (ADU-S100) Novartis Study of the Safety and Efficacy of MIW815 With PDR001 to Patients with Advanced/Metastatic Solid Tumors or Lymphomas Solid tumors Lymphomas Recruiting Phase 1
NCT03010176 MK-1454 Merck Sharp and Dohme Corp. Study of MK-1454 Alone or in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors or Lymphomas Solid tumors Lymphomas Recruiting Phase 1